Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Studio su Axicabtagene Ciloleucel somministrato con steroidi in partecipanti con linfoma a grandi cellule B recidivato o refrattario (ZUMA-24)

19 ottobre 2026 aggiornato da: Kite, A Gilead Company

Uno studio multicentrico di fase 2 in aperto che valuta la sicurezza e l'efficacia di Axicabtagene ciloleucel in concomitanza con steroidi profilattici in soggetti con linfoma a grandi cellule B recidivato o refrattario in regime ambulatoriale

The goal of this clinical study was to learn more about the study drug, axicabtagene ciloleucel, in participants with relapsed or refractory large B-cell lymphoma (LBCL) in the outpatient setting.

Panoramica dello studio

Stato

Completato

Condizioni

Intervento / Trattamento

Descrizione dettagliata

Participants who completed at minimum 18 months follow up were transitioned to a separate long-term follow-up study (study KT-US-982-5968) to complete the remainder of the 15-year follow-up assessments.

Tipo di studio

Interventistico

Iscrizione (Effettivo)

35

Fase

  • Fase 2

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

    • California
      • Duarte, California, Stati Uniti, 91010
        • City of Hope (City of Hope National Medical Center, City of Hope Medical Center)
      • Los Angeles, California, Stati Uniti, 90025
        • UCLA
    • Colorado
      • Denver, Colorado, Stati Uniti, 80218
        • Colorado Blood Cancer Institute
    • Maryland
      • Baltimore, Maryland, Stati Uniti, 21201
        • University of Maryland Greenebaum Comprehensive Cancer Center
    • Michigan
      • Detroit, Michigan, Stati Uniti, 48201
        • Barbara Ann Karmanos Cancer Institute
    • New Jersey
      • Hackensack, New Jersey, Stati Uniti, 07601
        • John Theurer Cancer Center at Hackensack University Medical Center
    • Ohio
      • Cincinnati, Ohio, Stati Uniti, 45242
        • Oncology Hematology Care Clinical Trials, LLC
    • South Carolina
      • Greenville, South Carolina, Stati Uniti, 29615
        • Prisma Health - Upstate
    • Tennessee
      • Nashville, Tennessee, Stati Uniti, 37203
        • Tennessee Oncology, PLLC
      • Nashville, Tennessee, Stati Uniti, 37232
        • Henry-Joyce Cancer Clinic
    • Texas
      • San Antonio, Texas, Stati Uniti, 78229
        • Methodist Healthcare System of San Antonio
    • Utah
      • Murray, Utah, Stati Uniti, 84107
        • Intermountain Healthcare
      • Salt Lake City, Utah, Stati Uniti, 84112
        • Huntsman Cancer Institute, University of Utah
    • Virginia
      • Charlottesville, Virginia, Stati Uniti, 22908
        • University of Virginia Health System
      • Norfolk, Virginia, Stati Uniti, 23502
        • Virginia Oncology Associates
      • Richmond, Virginia, Stati Uniti, 23219
        • Virginia Commonwealth University

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

18 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Key Inclusion Criteria:

  • Histologically confirmed large B-cell lymphoma (LBCL), including the following types defined by World Health Organization (WHO) 2016 classification, by local pathology laboratory assessment, are eligible as defined below:

    • Diffuse large B-cell lymphoma (DLBCL) not otherwise specified.
    • High-grade B-cell lymphoma (HGBL) with or without MYC and BCL2 and/or BCL6 rearrangement.
    • DLBCL associated with chronic inflammation; Epstein-Barr virus (EBV) + DLBCL.
    • Primary mediastinal (thymic) LBCL.
    • Primary cutaneous DLBCL, leg type.
    • Transformation of follicular lymphoma to DLBCL will also be included.
  • Relapsed or refractory disease after 1 or more lines of therapy.

  • Individuals must have received adequate prior therapy including:

    • Anti-CD20 monoclonal antibody AND
    • An anthracycline-containing chemotherapy regimen.
  • At least 1 measurable lesion according to the Lugano Response Criteria for Malignant Lymphoma. Lesions that have been previously irradiated will be considered measurable only if progression has been documented following completion of radiation therapy.

  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

  • Individual agrees to outpatient treatment setting and to adhere to the prespecified clinical monitoring requirements.

Key Exclusion Criteria:

  • History of autologous or allogeneic stem cell transplant.
  • Prior cluster of differentiation (CD)19 targeted therapy.
  • Prior chimeric antigen receptor therapy or other genetically modified T-cell therapy.
  • Presence of fungal, bacterial, viral, or other infection that is uncontrolled or requiring intravenous (IV) antimicrobials for management. Simple urinary tract infection and uncomplicated bacterial pharyngitis are permitted if responding to active treatment and after consultation with the Kite medical monitor.
  • Individuals with detectable cerebrospinal fluid malignant cells, brain metastases, or with a history of central nervous system (CNS) lymphoma or primary CNS lymphoma. DLBCL epidural involvement should be considered as positive CNS disease.
  • In the investigator's judgment, the individual is unlikely to complete all protocol-required study visits or procedures, including follow-up visits, or comply with the study requirements for participation.

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: N / A
  • Modello interventistico: Assegnazione di gruppo singolo
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Axicabtagene Ciloleucel

Participants will receive lymphodepleting chemotherapy (cyclophosphamide 500 mg/m^2/day and fludarabine 30 mg/m^2/day) over 3 days (Days -5, -4, and -3) followed by prophylactic corticosteroid treatment with 10 mg dexamethasone on Day 0 (prior to axicabtagene ciloleucel), Day 1, and Day 2. Participants will receive axicabtagene ciloleucel consisting of a single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells on Day 0 (following dexamethasone 10 mg) at a target dose of 2 x 10^6 cells/kg.

Administered intravenously

Administered intravenously

Administered intravenously

Altri nomi:
  • Yescarta®

Administered orally or intravenously

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Percentage of Participants With Treatment-emergent Cytokine Release Syndrome (CRS) as Per Severity
Lasso di tempo: Up to 2.2 years

CRS were identified via collection of the syndrome on a case report form specifically designed to collect CRS. Individual symptoms of CRS were separately collected on the Adverse Event (AE) log and were linked to the CRS syndrome. CRS events were graded per the revised grading system proposed by Lee et al 2014. Grade 1: Symptoms are not life threatening and require symptomatic treatment only; Grade 2: Symptoms require and respond to moderate intervention; Grade 3: Symptoms require and respond to aggressive intervention; Grade 4: Life-threatening symptoms; Grade 5: Death.

Up to 2.2 years
Percentage of Participants With Treatment-emergent Neurologic Events as Per Severity
Lasso di tempo: Up to 2.2 years

Neurological events were identified with a search strategy based on known neurologic toxicities associated with anti-CD19 immunotherapy. The search strategy focused on central nervous system toxicity, without regard to temporal relationship and concomitant conditions. Neurologic events were graded by Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. Grade 1: Mild, Grade 2: Moderate, Grade 3: Severe, Grade 4: Life-threatening consequences, Grade 5: Death.

Up to 2.2 years

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Time to Onset of CRS Following Axicabtagene Ciloleucel Administration
Lasso di tempo: Up to 2.2 years

Time to onset was defined as the earliest start date of CRS minus the axicabtagene ciloleucel infusion date plus 1. Participants without CRS by the data cutoff were censored at death date if participant died or last known alive date if participant was still alive; participants who withdrew consent were censored at end of study date. Kaplan-Meier (KM) estimates was used for analyses.

Up to 2.2 years
Time to Onset of Neurologic Events Following Axicabtagene Ciloleucel Administration
Lasso di tempo: Up to 2.2 years

Time to onset was defined as the earliest start date of neurologic event minus the axicabtagene ciloleucel infusion date plus 1. Participants without neurologic event by the data cutoff were censored at death date if participant died or last known alive date if participant was still alive; participants who withdrew consent were censored at end of study date. KM estimates was used for analyses.

Up to 2.2 years
Duration of CRS Following Axicabtagene Ciloleucel Administration
Lasso di tempo: Up to 2.2 years

Duration was defined as the latest end date of CRS minus the start date of the earliest CRS plus 1. Participants with unresolved or ongoing CRS by the data cutoff were censored at death date if participant died or last known alive date if participant is still alive; participants who withdrew consent, were censored at end of study date. KM estimates was used for analyses.

Up to 2.2 years
Duration of Neurologic Events Following Axicabtagene Ciloleucel Administration
Lasso di tempo: Up to 2.2 years

Duration was defined as the latest end date of neurologic event minus the start date of the earliest neurologic event plus 1. Participants with unresolved or ongoing neurologic event by the data cutoff were censored at death date if participant died or last known alive date if participant was still alive; participants who withdrew consent were censored at end of study date. KM estimates was used for analyses.

Up to 2.2 years
Percentage of Participants Hospitalized Within 72 Hours of Axicabtagene Ciloleucel Infusion
Lasso di tempo: Within 72 hours of axicabtagene ciloleucel infusion on Day 0

Hospitalized within 72 hours refers to 72 hours from the time when axicabtagene ciloleucel infusion starts.

Within 72 hours of axicabtagene ciloleucel infusion on Day 0
Percentage of Participants Hospitalized Within 4 Days of Axicabtagene Ciloleucel Infusion
Lasso di tempo: Within 4 days of axicabtagene ciloleucel infusion (from Day 0 to Day 3)

Hospitalization within 4 days refers to the period from Day 0 to Day 3 following axicabtagene ciloleucel infusion.

Within 4 days of axicabtagene ciloleucel infusion (from Day 0 to Day 3)
Percentage of Participants Hospitalized Within 7 Days of Axicabtagene Ciloleucel Infusion
Lasso di tempo: Within 7 days of axicabtagene ciloleucel infusion (from Day 0 to Day 6)

Hospitalization within 7 days refers to the period from Day 0 to Day 6 following axicabtagene ciloleucel infusion.

Within 7 days of axicabtagene ciloleucel infusion (from Day 0 to Day 6)
Percentage of Participants Hospitalized Within 14 Days of Axicabtagene Ciloleucel Infusion
Lasso di tempo: Within 14 days of axicabtagene ciloleucel infusion (from Day 0 to Day 13)

Hospitalization within 14 days refers to the period from Day 0 to Day 13 following axicabtagene ciloleucel infusion.

Within 14 days of axicabtagene ciloleucel infusion (from Day 0 to Day 13)
Percentage of Participants Hospitalized Within 30 Days of Axicabtagene Ciloleucel Infusion
Lasso di tempo: Within 30 days of axicabtagene ciloleucel infusion (from Day 0 to Day 29)

Hospitalization within 30 days refers to the period from Day 0 to Day 29 following axicabtagene ciloleucel infusion.

Within 30 days of axicabtagene ciloleucel infusion (from Day 0 to Day 29)
Duration of Initial Hospitalization After Axicabtagene Ciloleucel Infusion
Lasso di tempo: Up to 2.2 years
Up to 2.2 years
Percentage of Intensive Care Unit (ICU) Admitted Participants
Lasso di tempo: Up to 30 days
Up to 30 days
Duration of ICU Admission During First Hospitalization After Axicabtagene Ciloleucel Infusion
Lasso di tempo: Up to 2.2 years
Up to 2.2 years
Percentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs)
Lasso di tempo: Up to 2.2 years

An AE was defined as any untoward medical occurrence in a clinical trial participant. The event did not necessarily have a relationship with study treatment. TEAEs were defined as any adverse event with onset on or after the axicabtagene ciloleucel infusion.

Up to 2.2 years
Percentage of Participants Experiencing Treatment-Emergent Serious Adverse Events (TESAEs)
Lasso di tempo: Up to 2.2 years

A serious adverse event (SAEs) was defined as an event that, at any dose, resulted in death, a life-threatening situation, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability/incapacity, a congenital anomaly/birth defect, or a medically important event or reaction. TESAEs were defined as any serious adverse event with onset on or after the axicabtagene ciloleucel infusion.

Up to 2.2 years
Number of Participants With European Quality of Life Five Dimensions Five Levels Scale (EQ-5D-5L) Score
Lasso di tempo: Baseline, Week 4, Month 3, Month 6

The EQ-5D-5 levels (EQ-5D-5L) is a standardized measure of health status of the participant that provides a simple, generic measure of health for clinical and economic appraisal. EQ-5D-5L consists of 2 components: a descriptive system of the participant's health and EuroQoL visual analogue scale (EQ-VAS). The descriptive system comprises the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems.

Here Baseline corresponds to Screening (within 28 days before enrollment/leukapheresis).

Baseline, Week 4, Month 3, Month 6
EQ-5D-5L Visual Analogue Scale (EQ-VAS) Score
Lasso di tempo: Baseline, Week 4, Month 3, Month 6

The EQ-VAS is a vertical VAS for recording self-rated current Health-Related Quality of Life (HRQoL) state reported from 0, described as "the worst health you can imagine", to 100, described as "the best health you can imagine" Rating gets recorded on a vertical VAS in which the endpoints are labeled best imaginable health state is 100 (on the top) and worst imaginable health state is 0 (on the bottom). Higher scores of EQ-VAS indicate better health.

Here Baseline corresponds to Screening (within 28 days before enrollment/leukapheresis).

Baseline, Week 4, Month 3, Month 6
Percentage of Participants With Objective Response (OR) According to Investigator Assessment Per Lugano Response Criteria for Malignant Lymphoma
Lasso di tempo: Up to 2.5 years

OR: complete response (complete metabolic response[CMR]; complete radiologic response[CRR]) or partial response (partial MR [PMR]; partial RR [PRR]). CMR: positron emission tomography(PET) 5-point scale(5-PS) of 1-3 with/without residual mass; no new sites/evidence of fluorodeoxyglucose(FDG)-avid disease in bone marrow(BM).CRR: target nodes/nodal masses regressed to ≤1.5cm in longest transverse diameter(LDi) of lesion;no extra lymphatic sites;absent nonmeasured lesion(NMLs);organ enlargement regress to normal;no new sites;BM normal by morphology.PMR:5PS scores 4/5 with reduced uptake compared to baseline,residual masses of any size;no new sites;residual uptake higher than uptake in normal BM,reduced compared with baseline.PRR:≥50% decrease in sum of product of perpendicular diameters up to 6 target measurable nodes & extranodal sites;absent/normal,regressed but no increase of NMLs;spleen regressed by >50%;no new sites of disease. 95% CI were calculated by Clopper-Pearson method.

Up to 2.5 years
Percentage of Participants With Complete Response (CR) According to Investigator Assessment Per Lugano Response Criteria for Malignant Lymphoma
Lasso di tempo: Up to 2.5 years

Complete response is defined as participants with CMR and CRR. CMR: PET 5-PS scores of 1-3 with or without residual mass; no new sites/evidence of FDG-avid disease in bone marrow. CRR: target nodes/nodal masses regressed to ≤ 1.5cm in LDi of lesion; no extra lymphatic sites; absent NMLs; organ enlargement regress to normal; no new sites; and bone marrow normal by morphology. 95% CI were calculated by Clopper-Pearson method. Percentages were rounded off.

Up to 2.5 years
Duration of Response (DOR) According to Investigator Assessment Per Lugano Response Criteria for Malignant Lymphoma
Lasso di tempo: Up to 2.5 years

DOR is the time from first OR to disease progression (PD) or death from any cause. OR is defined in outcome measure (OM) 19. PD: Progressive Metabolic Disease: 5PS score 4 or 5 with increase in intensity of uptake from baseline; new FDG-avid foci consistent with lymphoma at interim time point or end of treatment assessment or consistent with lymphoma rather than another etiology; new or recurrent FDG-avid foci in bone marrow; Progressive Radiologic Disease: individual node/lesion must be abnormal with LDi >1.5cm, increase by ≥ 50% from cross product of LDi and perpendicular diameter nadir and increase in LDi or shortest transverse diameter, shortest axis perpendicular to LDi; splenomegaly: increase in length by > 50%; new or recurrent splenomegaly; new or clear progression of preexisting NMLs; new lesion; new or recurrent bone marrow involvement. KM estimates was used for analyses.

Up to 2.5 years
Progression-free Survival (PFS) According to Investigator Assessment Per Lugano Response Criteria for Malignant Lymphoma
Lasso di tempo: Up to 2.5 years

PFS was defined as the time from axicabtagene ciloleucel infusion date to the date of disease progression or, if no disease progression, the date of death due to any cause. PD: Progressive Metabolic Disease: 5PS score 4 or 5 with increase in intensity of uptake from baseline; new FDG-avid foci consistent with lymphoma at interim time point or end of treatment assessment or consistent with lymphoma rather than another etiology; new or recurrent FDG-avid foci in bone marrow; Progressive Radiologic Disease: individual node/lesion must be abnormal with LDi >1.5cm, increase by ≥ 50% from cross product of LDi and perpendicular diameter nadir and increase in LDi or shortest transverse diameter, shortest axis perpendicular to LDi; splenomegaly: increase in length by > 50%; new or recurrent splenomegaly; new or clear progression of preexisting NMLs; new lesion; new or recurrent bone marrow involvement. KM estimates was used for analyses.

Up to 2.5 years
Event Free Survival (EFS) According to Investigator Assessment Per Lugano Response Criteria for Malignant Lymphoma
Lasso di tempo: Up to 2.5 years

EFS is defined as the time from axicabtagene ciloleucel infusion to the earliest date of disease progression, commencement of new anti-lymphoma therapy (excluding SCT), or death from any cause. PD: Progressive Metabolic Disease: 5PS score 4 or 5 with increase in intensity of uptake from baseline; new FDG-avid foci consistent with lymphoma at interim time point or end of treatment assessment or consistent with lymphoma rather than another etiology; new or recurrent FDG-avid foci in bone marrow; Progressive Radiologic Disease: individual node/lesion must be abnormal with LDi >1.5cm, increase by ≥ 50% from cross product of LDi and perpendicular diameter nadir and increase in LDi or shortest transverse diameter, shortest axis perpendicular to LDi; splenomegaly: increase in length by > 50%; new or recurrent splenomegaly; new or clear progression of preexisting NMLs; new lesion; new or recurrent bone marrow involvement. KM estimates was used for analyses.

Up to 2.5 years
Overall Survival (OS)
Lasso di tempo: Up to 2.5 years

OS was defined as the time from the axicabtagene ciloleucel infusion date to the date of death from any cause. KM estimates was used for analyses.

Up to 2.5 years
Peak Serum Levels of Homeostatic/Proliferative Cytokines: Interleukin (IL)-2, IL-7, and IL-15
Lasso di tempo: From axicabtagene ciloleucel infusion (Day 0) up to Day 28

Peak is defined as the maximum analyte level in blood measured after infusion up to Day 28.

From axicabtagene ciloleucel infusion (Day 0) up to Day 28
Peak Serum Levels of Inflammatory and Immune Modulating Cytokines: Interferon Gamma (IFN-γ), IL-1, IL-6, IL- 13, IL-17, IL-1RA, Granulocyte-macrophage Colony Stimulating Factor (GM-CSF), Tumor Necrosis Factor-Alpha (TNF-α), IL-12p40, and IL-12p70
Lasso di tempo: From axicabtagene ciloleucel infusion (Day 0) up to Day 28

Peak is defined as the maximum analyte level in blood measured after axicabtagene ciloleucel infusion up to Day 28.

From axicabtagene ciloleucel infusion (Day 0) up to Day 28
Peak Serum Levels of Immune Effector Molecules: Granzyme A and Granzyme B
Lasso di tempo: From axicabtagene ciloleucel infusion (Day 0) up to Day 28

Peak is defined as the maximum analyte level in blood measured after axicabtagene ciloleucel infusion up to Day 28.

From axicabtagene ciloleucel infusion (Day 0) up to Day 28
Peak Serum Levels of Immune Effector Molecules: Perforin
Lasso di tempo: From axicabtagene ciloleucel infusion (Day 0) up to Day 28

Peak is defined as the maximum analyte level in blood measured after axicabtagene ciloleucel infusion up to Day 28.

From axicabtagene ciloleucel infusion (Day 0) up to Day 28
Peak Serum Levels of Acute Phase Response Proteins: Serum Amyloid A (SAA)
Lasso di tempo: From axicabtagene ciloleucel infusion (Day 0) up to Day 28

Peak is defined as the maximum analyte level in blood measured after axicabtagene ciloleucel infusion up to Day 28.

From axicabtagene ciloleucel infusion (Day 0) up to Day 28
Peak Serum Levels of the Acute Phase Response Proteins: C-Reactive Protein (CRP)
Lasso di tempo: From axicabtagene ciloleucel infusion (Day 0) up to Day 28

Peak is defined as the maximum analyte level in blood measured after axicabtagene ciloleucel infusion up to Day 28.

From axicabtagene ciloleucel infusion (Day 0) up to Day 28
Peak Serum Levels of the Acute Phase Response Proteins: Ferritin
Lasso di tempo: From axicabtagene ciloleucel infusion (Day 0) up to Day 28

Peak is defined as the maximum analyte level in blood measured after axicabtagene ciloleucel infusion up to Day 28.

From axicabtagene ciloleucel infusion (Day 0) up to Day 28
Peak Serum Levels of the Immune Activation Marker: Soluble IL-2 Receptor Alpha (sIL-2Rα)
Lasso di tempo: From axicabtagene ciloleucel infusion (Day 0) up to Day 28

Peak is defined as the maximum analyte level in blood measured after axicabtagene ciloleucel infusion up to Day 28.

From axicabtagene ciloleucel infusion (Day 0) up to Day 28
Peak Serum Levels of Chemokines: IL-8, C-X-C Motif Chemokine Ligand-10 (CXCL-10), and Monocyte Chemotactic Protein-1 (MCP-1)
Lasso di tempo: From axicabtagene ciloleucel infusion (Day 0) up to Day 28

Peak is defined as the maximum analyte level in blood measured after axicabtagene ciloleucel infusion up to Day 28.

From axicabtagene ciloleucel infusion (Day 0) up to Day 28
Peak Blood Levels of Axicabtagene Ciloleucel Chimeric Antigen Receptor (CAR) T-cells
Lasso di tempo: Up to 24 months

Peak is defined as the maximum number of CAR T-cells in blood measured after axicabtagene ciloleucel infusion.

Up to 24 months

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Investigatori

  • Direttore dello studio: Kite Study Director, Kite, A Gilead Company

Pubblicazioni e link utili

La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

9 agosto 2022

Completamento primario (Effettivo)

24 novembre 2025

Completamento dello studio (Effettivo)

24 novembre 2025

Date di iscrizione allo studio

Primo inviato

13 luglio 2022

Primo inviato che soddisfa i criteri di controllo qualità

13 luglio 2022

Primo Inserito (Effettivo)

15 luglio 2022

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

12 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

19 ottobre 2026

Ultimo verificato

1 ottobre 2026

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • KT-US-482-0137

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

SÌ

Descrizione del piano IPD

Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at https://www.gileadclinicaltrials.com/transparency-policy#Commitment

Periodo di condivisione IPD

18 months after study completion

Criteri di accesso alla condivisione IPD

A secured external environment with username, password, and RSA code.

Tipo di informazioni di supporto alla condivisione IPD

  • STUDIO_PROTOCOLLO
  • LINFA

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

Sì

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .